Canada Markets close in 1 hr 41 mins

Pascal Biosciences Inc. (PAS.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1400-0.0100 (-6.67%)
As of 1:04PM EDT. Market open.

Pascal Biosciences Inc.

400 Burrard Street
Suite 1780
Vancouver, BC V6C 3A6
604 880 7250

Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Dr. Patrick W. GrayCEO & Director204.34kN/A1952
Ms. Judith F. Dalling L.L.B.CFO & Corp. Sec.65kN/A1955
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Pascal Biosciences Inc., a biopharmaceutical company, researches and develops products for the treatment of cancer, and for the enhancement of immune system. Its development portfolio includes PAS-403, a small molecule therapeutic advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory molecule to enhance the efficacy of checkpoint inhibitors. The company is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was founded in 2013 and is headquartered in Vancouver, Canada.

Corporate Governance

Pascal Biosciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.